Group 1 - The company, 康臣药业 (01681), announced a share buyback plan on November 7, 2025, with an investment of HKD 7.4928 million to repurchase 505,000 shares [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 FF305 公司名稱： 康臣葯業集團有限公司 呈交日期： 2025年11月7日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 不適用 | | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 01681 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | ...

Summary of Key Points Core Viewpoint - A total of 30 companies conducted share buybacks on November 6, 2025, with China Feihe (06186) leading in both the number of shares repurchased and the total amount spent on buybacks [1]. Group 1: Buyback Details - China Feihe (06186) repurchased 6.806 million shares for a total of 29.4298 million yuan, representing 0.746% of its total share capital [2]. - Kexin Pharmaceutical-B (02171) repurchased 1.734 million shares for 26.3078 million yuan, accounting for 0.380% of its total share capital [2]. - COSCO Shipping Holdings (01919) repurchased 1.53 million shares for 20.9869 million yuan, which is 0.409% of its total share capital [2]. Group 2: Other Notable Buybacks - Gushengtang (02273) repurchased 493,500 shares for 13.7699 million yuan, representing 3.435% of its total share capital [2]. - China Petroleum & Chemical Corporation (00386) repurchased 2.398 million shares for 10.1066 million yuan, which is 0.100% of its total share capital [2]. - Lianyi Technology-W (09959) repurchased 2.38 million shares for 7.4745 million yuan, accounting for 4.298% of its total share capital [2]. Group 3: Additional Companies - Other companies that conducted buybacks include: - Ruisheng Technology (02018) with 165,000 shares repurchased for 6.5033 million yuan [2]. - MGM China (02282) with 400,000 shares repurchased for 6.3701 million yuan [2]. - Huajian Medical (01931) with 922,000 shares repurchased for 5.9985 million yuan [2]. Group 4: Smaller Buybacks - Companies with smaller buyback amounts include: - Yidian Cloud (02416) with 130,000 shares repurchased for 264,000 yuan [3]. - International Home Retail (01373) with 150,000 shares repurchased for 118,500 yuan [3]. - Mobi Development (00947) with 70,000 shares repurchased for 1.167 million yuan [3].

Core Viewpoint - 康臣药业 (01681) has proposed a share award plan to incentivize and reward individuals contributing to the group's growth and development, with the board's decision made on November 6, 2025 [1] Summary by Relevant Categories - **Company Initiatives** - The board of 康臣药业 has resolved to adopt a share award plan as part of its strategy to motivate participants involved in the company's growth [1]

Core Viewpoint - 康臣药业 has proposed a share award plan to incentivize and reward individuals contributing to the company's growth and development, with the board's decision made on November 6, 2025 [1] Group 1 - The share award plan aims to motivate participants involved in the company's progress [1]

Core Viewpoint - 康臣药业 has proposed a share award plan to incentivize and reward individuals contributing to the company's growth and development, pending shareholder approval at a special meeting [1] Summary by Relevant Sections - **Share Award Plan** - The board of 康臣药业 has decided to propose the adoption of a share award plan on November 6, 2025 [1] - This plan aims to incentivize and reward participants involved in the company's growth and development [1] - **Regulatory Compliance** - The proposed share award plan will constitute a new share scheme under Chapter 17 of the Listing Rules [1] - According to Listing Rule 17.02(1)(a), the adoption of the share award plan requires approval from shareholders at a special general meeting [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部份內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 （於開曼群島註冊成立的有限公司） （股份代號：1681） 建議採納股份獎勵計劃 建議採納股份獎勵計劃 為使本公司可授予股份獎勵，作為對參與本集團成長及發展之人士的激勵及回 報的一部份，董事局於2025年11月6日議決建議採納股份獎勵計劃。 股份獎勵計劃（倘獲採納）將構成上市規則第十七章項下涉及授予新股份之股份 計劃。根據上市規則第17.02(1)(a)條，採納股份獎勵計劃須（其中包括）於股東 特別大會上獲得股東批准。 一般事項 董事局將召開股東特別大會，以考慮及酌情批准（其中包括）建議採納股份獎勵 計劃。 一份載有（其中包括）(i)建議採納股份獎勵計劃之詳情；及(ii)召開股東特別大會 通告之通函將根據上市規則規定適時寄發予股東。 為使本公司可授予股份獎勵，作為對參與本集團成長及發展之人士的激勵及回報 的一部份，董事局於2025年11月6日議決建議採納股份獎勵計劃。 2013年購股權計劃及2024年購股權 ...

建議就持有庫存股修訂現有組織章程大綱及細則 以及採納新組織章程大綱及細則 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容所產生或因依 賴該等內容而引致的任何損失承擔任何責任。 （於開曼群島註冊成立的有限公司） （股份代號：1681） 本公告乃由康臣葯業集團有限公司（「本公司」）根據香港聯合交易所有限公司證券 上市規則（「上市規則」）第13.51(1)條而作出，內容有關建議修訂本公司第二次經 修訂及重述的組織章程大綱及細則（「現有組織章程大綱及細則」）。 主席 安猛 香港，2025年11月6日 於本公告日期，董事局成員包括執行董事安猛先生及楊玉川先生；非執行董事張 麗華博士及朱荃教授；以及獨立非執行董事馮仲實先生、李義凱教授、李灼光先 生及段威武先生。 本公司董事（「董事」）局（「董事局」）建議對現有組織章程大綱及細則作出建議修 訂，以讓本公司得以根據開曼群島適用法律及上市規則近期有關庫存股的修訂， 持有及出售任何已購回本公司股份作為庫存股，並作出其他內部變更（「建議修 訂」），以及採納本公司第三次經修訂 ...

Core Viewpoint - 康臣药业 announced a share buyback plan, indicating confidence in its stock value and potential for future growth [1] Summary by Category Company Actions - 康臣药业 plans to repurchase 100,000 shares at a total cost of 1.5009 million HKD, with each share priced between 15 and 15.04 HKD [1]

Group 1 - Company announced a share buyback of 100,000 shares at a cost of HKD 1.5 million on November 6 [1]